"10.1371_journal.pone.0140900","plos one","2015-10-26T00:00:00Z","Ilias Stefas; Sylvia Tigrett; Grégor Dubois; Marco Kaiser; Estelle Lucarz; Delphine Gobby; Dorothy Bray; Heinz Ellerbrok; Jean Pierre Zarski; Francisco Veas","ApoH-Technologies, Faculté de Pharmacie, Université de Montpellier, Montpellier, France; Institut de Recherche pour le Développement, UMR-Ministère de la Défense 3, Laboratoire d’Immuno-Physiopathologie Moléculaire Comparée, Faculté de Pharmacie, Montpellier, France; GenExpress GmbH, Berlin, Germany; Immunoclin Corporation, Washington, DC, United States of America; Robert Koch-Institute, Centre for Biological Threats and Special Pathogens, Highly Pathogenic Viruses, Berlin, Germany; Clinique d’Hépato-gastroentérologie, Centre Hospitalier Universitaire de Grenoble, IAB, INSERM U823, Grenoble, France","Conceived and designed the experiments: IS FV. Performed the experiments: ST GD DG EL-B MK. Analyzed the data: IS FV ST GD EL-B DB DG MK HE. Contributed reagents/materials/analysis tools: JPZ HE DB. Wrote the paper: IS FV. Obtained authorization of the ethical regulatory procedures: DB.","IRD and ApoH-Technologies (ApoH-T) have filed patent applications on detection of pathogens, including HCV infection (FR2927172(B1) “Detecting infectious components in a biological fluid sample comprises contacting microbeads loaded with beta 2 glycoprotein I with the sample in the presence of oxidizing metal ions”. Inventors: STEFAS ILIAS [FR]; VEAS FRANCISCO [FR]; Applicant: ApoH:Technologies SA (www.apohtech.com); Application number: FR20080000553 20080201; Priority number: FR20080000553 20080201; Classification: (i) international: C12Q1/04; C12Q1/70; G01N33/569; G01N33/68; (ii) cooperative: C12Q1/04; G01N33/56911; G01N33/56983). Marketed products are on www.apohtech.com. Francisco Veas and Ilias Stefas respectively, serve as scientific advisor for ApoH-T and CEO of the company. In addition, ST-G and EL-B are part of the ApoH-T staff and DG was part of ApoH-T. DB is the CEO of Immunoclin Corp. MK and HE are employed by GenExpress GmbH. MK and HE are consultants for ImmunoClin Corporations. There are no further patents, products in development, or marketed products to declare. This does not alter the authors adherence to all PLOS policies on sharing data and materials.","2015","10","Ilias Stefas","IS",10,TRUE,2,5,9,2,TRUE,TRUE,TRUE,1,"5",FALSE
